An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Metformin prolonged release tablets 1000 mg of Pinnacle Life Science Pvt. Ltd., in comparison with Glucophage®1000 mg XR tablets (Metformin Hydrochloride prolonged release tablets) of Merck Sante S.A.S in healthy, adult, human subjects under fasting conditions.
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study of Metformin prolonged release tablets 1000 mg of Pinnacle Life Science Pvt. Ltd., in comparison with Glucophage®1000 mg XR tablets (Metformin Hydrochloride prolonged release tablets) of Merck Sante S.A.S in healthy, adult, human subjects under fed conditions.
A randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, oral bioequivalence study comparing Test Product, Fixed Dose Combination of Dapagliflozin 10mg + Sitagliptin 100mg tablets of Pinnacle Life Science Pvt. Ltd., India and Reference Products, FORXIGA® (Dapagliflozin) 10 mg tablets of Astra Zeneca Ltd., and Januvia (Sitagliptin) 100mg tablets of MSD Ltd., in healthy, adult, human male subjects under fasting conditions
100 Clinical Results associated with Pinnacle Life Science Pvt Ltd.
0 Patents (Medical) associated with Pinnacle Life Science Pvt Ltd.
100 Deals associated with Pinnacle Life Science Pvt Ltd.
100 Translational Medicine associated with Pinnacle Life Science Pvt Ltd.